<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName archivearticle3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">Clin Case Rep</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2050-0904</journal-id><journal-id journal-id-type="publisher-id">CCR3</journal-id><journal-title-group><journal-title>Clinical Case Reports</journal-title></journal-title-group><issn pub-type="epub">2050-0904</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5715601</article-id><article-id pub-id-type="doi">10.1002/ccr3.1226</article-id><article-id pub-id-type="publisher-id">CCR31226</article-id><article-categories><subj-group subj-group-type="overline"><subject>Case Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Case Reports</subject></subj-group></article-categories><title-group><article-title>
<italic><styled-content style="fixed-case">PROS</styled-content>1</italic> novel splice&#x02010;site variant decreases protein S expression in patients from two families with thrombotic disease</article-title><alt-title alt-title-type="left-running-head">J. Menezes <italic>et al</italic>.</alt-title></title-group><contrib-group><contrib id="ccr31226-cr-0001" contrib-type="author"><name><surname>Menezes</surname><given-names>Juliane</given-names></name><xref ref-type="aff" rid="ccr31226-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ccr31226-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ccr31226-cr-0002" contrib-type="author"><name><surname>Ventura</surname><given-names>C&#x000e9;lia</given-names></name><xref ref-type="aff" rid="ccr31226-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="ccr31226-cr-0003" contrib-type="author"><name><surname>Costa</surname><given-names>Jo&#x000e3;o Matos</given-names></name><xref ref-type="aff" rid="ccr31226-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="ccr31226-cr-0004" contrib-type="author"><name><surname>Parreira</surname><given-names>Elsa</given-names></name><xref ref-type="aff" rid="ccr31226-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="ccr31226-cr-0005" contrib-type="author"><name><surname>Rom&#x000e3;o</surname><given-names>Lu&#x000ed;sa</given-names></name><xref ref-type="aff" rid="ccr31226-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ccr31226-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ccr31226-cr-0006" contrib-type="author" corresp="yes"><name><surname>Gon&#x000e7;alves</surname><given-names>Jo&#x000e3;o</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9359-8774</contrib-id><address><email>joao.goncalves@insa.min-saude.pt</email></address><xref ref-type="aff" rid="ccr31226-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ccr31226-aff-0005">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="ccr31226-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Human Genetics</named-content>
<institution>Instituto Nacional de Sa&#x000fa;de Doutor Ricardo Jorge</institution>
<named-content content-type="city">Lisbon</named-content>
<country country="PT">Portugal</country>
</aff><aff id="ccr31226-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Gene Expression and Regulation Group</named-content>
<named-content content-type="organisation-division">Biosystems &#x00026; Integrative Sciences Institute (BioISI)</named-content>
<named-content content-type="organisation-division">Faculdade de Ci&#x000ea;ncias</named-content>
<institution>Universidade de Lisboa</institution>
<named-content content-type="city">Lisbon</named-content>
<country country="PT">Portugal</country>
</aff><aff id="ccr31226-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Third Department of Internal Medicine</named-content>
<institution>Hospital Distrital de Santar&#x000e9;m</institution>
<named-content content-type="city">Santar&#x000e9;m</named-content>
<country country="PT">Portugal</country>
</aff><aff id="ccr31226-aff-0004">
<label><sup>4</sup></label>
<institution>Hospital Fernando Fonseca</institution>
<named-content content-type="city">Amadora</named-content>
<country country="PT">Portugal</country>
</aff><aff id="ccr31226-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Centre for Toxicogenomics and Human Health (ToxOmics)</named-content>
<named-content content-type="organisation-division">Genetics, Oncology and Human Toxicology</named-content>
<named-content content-type="organisation-division">Nova Medical School</named-content>
<institution>Universidade Nova de Lisboa</institution>
<named-content content-type="city">Lisbon</named-content>
<country country="PT">Portugal</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Jo&#x000e3;o Gon&#x000e7;alves, Department of Human Genetics, Instituto Nacional de Sa&#x000fa;de Doutor Ricardo Jorge, Av. Padre Cruz s/n, 1649&#x02010;016, Lisboa, Portugal. Tel: (+351) 217519320; Fax: (+351) 217526400; E&#x02010;mail: <email>joao.goncalves@insa.min-saude.pt</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2017</year></pub-date><volume>5</volume><issue>12</issue><issue-id pub-id-type="doi">10.1002/ccr3.2017.5.issue-12</issue-id><fpage>2062</fpage><lpage>2065</lpage><history><date date-type="received"><day>08</day><month>6</month><year>2017</year></date><date date-type="rev-recd"><day>04</day><month>9</month><year>2017</year></date><date date-type="accepted"><day>19</day><month>9</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 John Wiley & Sons Ltd. <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. <italic>Clinical Case Reports</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:CCR3-5-2062.pdf"/><abstract id="ccr31226-abs-0001"><title>Key Clinical Message</title><p>Our results prove that c.1871&#x02010;14T&#x0003e;G is causative of type I <styled-content style="fixed-case">PS</styled-content> deficiency, highlighting the importance of performing <styled-content style="fixed-case">mRNA</styled-content>&#x02010;based studies in order to evaluate variants pathogenicity. We evidence the increased risk of venous thromboembolism associated with this cryptic splice&#x02010;site variant if present in patients with <styled-content style="fixed-case">PS</styled-content> deficiency.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="ccr31226-kwd-0001"><italic><styled-content style="fixed-case">PROS</styled-content>1</italic></kwd><kwd id="ccr31226-kwd-0002">protein S deficiency</kwd><kwd id="ccr31226-kwd-0003">thrombophilia</kwd><kwd id="ccr31226-kwd-0004">thrombosis</kwd><kwd id="ccr31226-kwd-0005">venous thromboembolism</kwd></kwd-group><funding-group><award-group><funding-source>Funda&#x000e7;&#x000e3;o para a Ci&#x000ea;ncia e a Tecnologia</funding-source><award-id>SFRH/BPD/98360/2013</award-id><award-id>UID/BIM/00009/2013</award-id></award-group><award-group><funding-source>Centre for Toxicogenomics and Human Health&#x02014;ToxOmics</funding-source></award-group><award-group><funding-source>Genetics, Oncology and Human Toxicology</funding-source><award-id>UID/BIM/00009/2013</award-id></award-group></funding-group><counts><fig-count count="1"/><table-count count="0"/><page-count count="4"/><word-count count="2023"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>ccr31226</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.7 mode:remove_FC converted:05.12.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="ccr31226-cit-1001">
<source>Clinical Case Reports</source>
<year>2017</year>; <volume>5</volume>(<issue>12</issue>): <fpage>2062</fpage>&#x02013;<lpage>2065</lpage>
</mixed-citation>
</p></notes></front><body><sec id="ccr31226-sec-0001"><title>Introduction</title><p>Protein S (PS) is a widely studied protein with an important function in the downregulation of thrombin formation. Since its discovery in 1976, more than 400 variants have been described in PS gene (<italic>PROS1</italic>) associated with PS deficiency and as a risk factor for venous thromboembolism (VTE). We describe a novel variant, c.1871&#x02010;14T&#x0003e;G, in intron 14 of <italic>PROS1</italic> gene identified in two patients with PS deficiency from two unrelated families with a history of thrombotic disease. This alteration leads to a <italic>PROS1</italic> mRNA expression reduction, probably due to nonsense&#x02010;mediated mRNA decay. Our results suggest that c.1871&#x02010;14T&#x0003e;G is causative of type I PS deficiency in these patients, highlighting the importance of screening not only the coding and the most conserved intron&#x02013;exon junctions, but also perform mRNA&#x02010;based studies. We call attention to the potential increased risk of VTE in hereditary type I PS deficiency associated with this cryptic splice&#x02010;site variant.</p></sec><sec id="ccr31226-sec-0002"><title>Report</title><p>Hereditary PS deficiency (PSD) is an autosomal dominant disorder associated with an increased risk of venous thromboembolism (VTE) <xref rid="ccr31226-bib-0001" ref-type="ref">1</xref>, <xref rid="ccr31226-bib-0002" ref-type="ref">2</xref>. The genetic basis of PSD is heterogeneous and is also associated with phenotypic variability. More than 400 variants in PROS1 have been described, the vast majority being missense or nonsense variants, distributed along the coding region <xref rid="ccr31226-bib-0003" ref-type="ref">3</xref>. In this report, we describe a novel c.1871&#x02010;14T&#x0003e;G variant in <italic>PROS1</italic> intron 14, identified in two patients from two unrelated families, both with PSD and history of thrombotic disease.</p><p>Two unrelated Portuguese women were referred for genetic analysis of the <italic>PROS1</italic> gene due to PSD and clinical conditions associated with thromboembolism (Fig. <xref rid="ccr31226-fig-0001" ref-type="fig">1</xref>A, probands F1&#x02010;III2 and F2&#x02010;IV3). Plasma levels of total (TPS) and free protein S (FPS) antigen were below the lower limit of reference, suggesting type I PSD. After obtained informed consent, peripheral blood (PB) samples were collected for <italic>PROS1</italic> molecular analysis of patients F1&#x02010;III2 and F2&#x02010;IV3. PB was also available from patient F1&#x02010;III2 for mRNA studies, and from her mother and sister for <italic>PROS1</italic>, c.20210G&#x0003e;A Prothrombin and Factor V Leiden genetic testing.</p><fig fig-type="Figure" xml:lang="en" id="ccr31226-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>(A) Pedigrees from probands F1&#x02010;<styled-content style="fixed-case">III</styled-content>2 and F2&#x02010;<styled-content style="fixed-case">IV</styled-content>3. The arrow indicates each proband. Relevant results are below each family member: <styled-content style="fixed-case">FPS</styled-content>,<styled-content style="fixed-case"> TPS</styled-content>, Fc<styled-content style="fixed-case">PS</styled-content>&#x02014;free, total, and functional protein S, respectively. <styled-content style="fixed-case">CVT</styled-content>, cerebral venous thrombosis; <styled-content style="fixed-case">AMI</styled-content>, acute myocardial infarction. *Clinical diagnosis and laboratory analysis performed elsewhere. Orange and blue&#x02014;stand for <styled-content style="fixed-case">PS</styled-content> deficiency and <styled-content style="fixed-case">FV</styled-content> Leiden heterozygosity, respectively. Heterozygosity (hetz) for <italic><styled-content style="fixed-case">PROS</styled-content>1</italic> variant c.1871&#x02010;14T&#x0003e;G and the clinical condition are shadowed in gray. (B) <styled-content style="fixed-case">DNA</styled-content> sequence results of <italic><styled-content style="fixed-case">PROS</styled-content>1</italic> intron 14&#x02013;exon 15 junctions of F1&#x02010;<styled-content style="fixed-case">III</styled-content>2, F1&#x02010;<styled-content style="fixed-case">II</styled-content>4, and F2&#x02010;<styled-content style="fixed-case">IV</styled-content>3. Molecular analysis revealed that F1&#x02010;<styled-content style="fixed-case">III</styled-content>2 and F2&#x02010;<styled-content style="fixed-case">IV</styled-content>3 are heterozygous for <italic><styled-content style="fixed-case">PROS</styled-content>1</italic>: c.1871&#x02010;14T&#x0003e;G variant (<styled-content style="fixed-case">NCBI</styled-content> sequence reference: <styled-content style="fixed-case">NM</styled-content>_000313.3) that is predicted to activate new intronic cryptic acceptor splice site. (C) <italic><styled-content style="fixed-case">PROS</styled-content>1</italic> transcript amplification analysis of exon 14&#x02013;exon 15 junctions in a 2% agarose gel. The 150&#x02010;bp fragment in the control (C) and F1&#x02010;<styled-content style="fixed-case">III</styled-content>2 results from the amplification of the wild&#x02010;type (wt) allele, and the 163&#x02010;bp fragment found in F1&#x02010;<styled-content style="fixed-case">III</styled-content>2 is from amplification of the mutant allele. The 70&#x02010;bp fragment in the C and F1&#x02010;<styled-content style="fixed-case">III</styled-content>2 corresponds to <italic><styled-content style="fixed-case">GAPDH</styled-content></italic> (internal control) amplification. M: <styled-content style="fixed-case">NZYDNA</styled-content> ladder <styled-content style="fixed-case">VI</styled-content>; B: Mock. (D) Chromatogram of the 163&#x02010;bp <styled-content style="fixed-case">RT</styled-content>&#x02010;<styled-content style="fixed-case">PCR</styled-content> fragment from patient F1&#x02010;<styled-content style="fixed-case">III</styled-content>2. The sequence analysis revealed that c.1871&#x02010;14T&#x0003e;G variant resulted in the retention of the last 13 nucleotides from intron 14, inserted between exons 14 and 15 in <italic><styled-content style="fixed-case">PROS</styled-content>1</italic>
<styled-content style="fixed-case">mRNA</styled-content>. (E) Quantification of wt <italic><styled-content style="fixed-case">PROS</styled-content>1</italic>
<styled-content style="fixed-case">mRNA</styled-content> expression by real&#x02010;time <styled-content style="fixed-case">PCR</styled-content> from patient F1&#x02010;<styled-content style="fixed-case">III</styled-content>2. The expression levels of <italic><styled-content style="fixed-case">PROS</styled-content>1</italic>
<styled-content style="fixed-case">mRNA</styled-content> were normalized to the internal control <italic><styled-content style="fixed-case">GAPDH</styled-content></italic>
<styled-content style="fixed-case">mRNA</styled-content>. The values of <italic><styled-content style="fixed-case">PROS</styled-content>1</italic>
<styled-content style="fixed-case">mRNA</styled-content> amplicons from F1&#x02010;<styled-content style="fixed-case">III</styled-content>2 were compared to the control sample, arbitrarily set to 1. Patient F1&#x02010;<styled-content style="fixed-case">III</styled-content>2 produces 40% of total wt <italic><styled-content style="fixed-case">PROS</styled-content>1</italic>
<styled-content style="fixed-case">mRNA</styled-content> when compared to a healthy control (<italic>P</italic> = 0.035). (F) In silico prediction of c.1871&#x02010;14G&#x0003e;T variant in the <styled-content style="fixed-case">PROS</styled-content>1 protein sequence. The insertion in the mutant allele alters the reading frame and predicting a truncated protein that loses all amino acids encoded by exon 15 and gains a premature stop codon.</p></caption><graphic id="nlm-graphic-3" xlink:href="CCR3-5-2062-g001"/></fig><p>As there were no other factors that could potentially result in a decrease in PS levels in patients F1&#x02010;III2 and F2&#x02010;IV3, hereditary type I PSD was suspected (Fig. <xref rid="ccr31226-fig-0001" ref-type="fig">1</xref>A). Standard molecular analysis of <italic>PROS1</italic>
<xref rid="ccr31226-bib-0004" ref-type="ref">4</xref> culminated with the identification of a T&#x0003e;G transversion at position&#x02010;14 of the acceptor splice site of intron 14 in patients F1&#x02010;III2 and F2&#x02010;IV3. This alteration was not identified in the mother of F1&#x02010;III2 (Fig. <xref rid="ccr31226-fig-0001" ref-type="fig">1</xref>B), suggesting that it is of paternal origin. To our knowledge, the <italic>PROS1</italic> c.1871&#x02010;14T&#x0003e;G variant was not described associated with PSD and it is very rare in the general population (rs754929347; MAF C = 0.000009/1). Analysis of this variant using the Alamut&#x02010;v2.2 interactive biosoftware predicted the creation of a new cryptic acceptor splice site (scores: SSF = 71.78; MaxEnt = 2.32 and HSF = 76.10).</p><p>As c.1871&#x02010;14T&#x0003e;G has a potential effect on intron 14&#x02013;exon 15 acceptor splice site, we decided to study its <italic>PROS1</italic> mRNA. For this purpose, RNA was isolated from fresh PB leukocytes (obtained from patient F1&#x02010;III2) and cDNA was amplified. As a result, two PCR products of 150&#x02010;bp and 163&#x02010;bp in the patient cDNA were amplified, unlike the healthy control sample in which only the wild&#x02010;type (wt) allele of 150&#x02010;bp was obtained, as expected (Fig. <xref rid="ccr31226-fig-0001" ref-type="fig">1</xref>C). To better characterize the 150&#x02010;bp and 163&#x02010;bp fragments, both were separately cloned and sequenced. We found, as expected, that the 150&#x02010;bp fragment from the patient and the control sample corresponds to the wt allele with the correct junction of exons 14 and 15 (data not shown). However, the 163&#x02010;bp fragment retained the last 13 nucleotides (nt) of intron 14 (Fig. <xref rid="ccr31226-fig-0001" ref-type="fig">1</xref>D). In order to quantitatively evaluate the expression level of wt <italic>PROS1</italic> mRNA in proband F1&#x02010;III2, we performed real&#x02010;time PCR using specific primers for the wt allele (Fig. <xref rid="ccr31226-fig-0001" ref-type="fig">1</xref>E). Our results demonstrated that the patient F1&#x02010;III2 sample has only 40% of total wt <italic>PROS1</italic> mRNA when compared to the healthy control (<italic>P</italic> = 0.035).</p><p>Finally, we decided to investigate how the retention of these 13 nt in the mRNA of <italic>PROS1</italic> would affect the PROS1 protein. In silico analysis using the ExPASy translate tool revealed that the additional 13 nt of the mutant allele, alters the reading frame, predicting a truncated protein that loses all amino acids encoded by exon 15 (green sequence) and creates a premature termination codon (PTC) 17 amino acids downstream (red sequence) (Fig. <xref rid="ccr31226-fig-0001" ref-type="fig">1</xref>F). However, nonsense&#x02010;mediated mRNA decay (NMD) may recognize and selectively degrades this mRNA carrying PTC, preventing the production of a truncated protein.</p><p>To date, only few studies have experimentally demonstrated the functional consequences of <italic>PROS1</italic> variants associated with type I PSD. Variants in <italic>PROS1</italic> leading to deleterious alleles, such as frameshift or splice&#x02010;site variants, result in significant sequence alterations and often introduce PTCs, as was demonstrated with this study. In addition, in silico splice&#x02010;site prediction tools are not enough to take definitive conclusions about the variants functional consequences. Additional mRNA&#x02010;based studies should be performed when putative splicing variants are identified. To elucidate the genetic causes underlying PSD and the heterogeneity observed in its phenotypic manifestation, it is essential to investigate the consequences of naturally occurring <italic>PROS1</italic> variants. Our results shed some light on the mechanism by which splice&#x02010;site variants can alter plasma PS levels.</p><p>Concerning the risk of VTE, both patients have PS levels below the lower limit of the reference range. This splicing variant probably results in a reduced synthesis of PS reflected in lower levels of FPS and TPS identified in the affected members of these two families, and possibly they have a putative increased risk of VTE as was reported in previous studies <xref rid="ccr31226-bib-0002" ref-type="ref">2</xref>, <xref rid="ccr31226-bib-0005" ref-type="ref">5</xref>. We also emphasize the occurrence of a thrombotic episode at an early age (26 years) in patient F1&#x02010;III1, which probably is related to the cumulative effect of the cosegregation of PROS1: c.1871&#x02010;14T&#x0003e;G and FV Leiden, another well&#x02010;known risk factor for thrombosis, demonstrating that the risk of thrombosis is higher in carriers of double defects.</p><p>In conclusion, we describe a novel c.1871&#x02010;14T&#x0003e;G splice&#x02010;site variant probably causative of type I PSD and supports the importance of the molecular and functional characterization of naturally occurring <italic>PROS1</italic> variants, such as mRNA&#x02010;based studies in the cases of putative splice&#x02010;site variants.</p></sec><sec id="ccr31226-sec-0004"><title>Authorship</title><p>JM: designed and performed the mRNA experiments, analyzed the results, and wrote the manuscript. CV: performed the molecular screening of <italic>PROS1</italic> gene and revised the manuscript. JMC and EP: established the clinical diagnosis of the index cases of family 1 and 2, respectively. LR: analyzed the results and revised the manuscript. JG: directed the molecular screening of <italic>PROS1</italic>, supervised the project, analyzed the results, and revised the manuscript.</p></sec><sec id="ccr31226-sec-0005"><title>Conflict of Interests</title><p>The authors state that they have no conflict of interests.</p></sec></body><back><ack id="ccr31226-sec-0003"><title>Acknowledgments</title><p>We thank Elizabeth Silva for technical support on total mRNA extraction, Rita Cert&#x000e3; for molecular analysis, Isabel Moreira for F2 and factor V Leiden genotyping and to our colleagues of Unidade de Tecnologia e Inova&#x000e7;&#x000e3;o for technical support with capillary electrophoresis. Juliane Menezes is supported by a fellowship from Funda&#x000e7;&#x000e3;o para a Ci&#x000ea;ncia e a Tecnologia (SFRH/BPD/98360/2013), and this work was partially funded by the Centre for Toxicogenomics and Human Health&#x02014;ToxOmics, Genetics, Oncology and Human Toxicology from Funda&#x000e7;&#x000e3;o para a Ci&#x000ea;ncia e a Tecnologia (UID/BIM/00009/2013).</p></ack><ref-list content-type="cited-references" id="ccr31226-bibl-0001"><title>References</title><ref id="ccr31226-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="ccr31226-cit-0001">
<string-name>
<surname>Gandrille</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Borgel</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Sala</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Espinosa&#x02010;Parrilla</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Simmonds</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Rezende</surname>
</string-name>, et al. <year>2000</year>
<article-title>Protein S deficiency: a database of mutations&#x02013;summary of the first update</article-title>. <source>Thromb. Haemost.</source>
<volume>84</volume>:<fpage>918</fpage>.<pub-id pub-id-type="pmid">11127877</pub-id></mixed-citation></ref><ref id="ccr31226-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ccr31226-cit-0002">
<string-name>
<surname>Alhenc&#x02010;Gelas</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Plu&#x02010;Bureau</surname>
</string-name>, <string-name>
<given-names>M. H.</given-names>
<surname>Horellou</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Rauch</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Suchon</surname>
</string-name>, and <collab collab-type="authors">GEHT genetic thrombophilia group</collab>
. <year>2016</year>
<article-title>PROS1 genotype phenotype relationships in a large cohort of adults with suspicion of inherited quantitative protein S deficiency</article-title>. <source>Thromb. Haemost.</source>
<volume>115</volume>:<fpage>570</fpage>&#x02013;<lpage>579</lpage>.<pub-id pub-id-type="pmid">26466767</pub-id></mixed-citation></ref><ref id="ccr31226-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ccr31226-cit-0003">
<string-name>
<surname>Stenson</surname>, <given-names>P. D.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Mort</surname>
</string-name>, <string-name>
<given-names>E. V.</given-names>
<surname>Ball</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Evans</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Hayden</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Heywood</surname>
</string-name>, et al. <year>2017</year>
<article-title>The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next&#x02010;generation sequencing studies</article-title>. <source>Hum. Genet.</source>
<volume>136</volume>:<fpage>665</fpage>&#x02013;<lpage>677</lpage>.<pub-id pub-id-type="pmid">28349240</pub-id></mixed-citation></ref><ref id="ccr31226-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="ccr31226-cit-0004">
<string-name>
<surname>Bustorff</surname>, <given-names>T. C.</given-names>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Freire</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Gago</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Crespo</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>David</surname>
</string-name>. <year>1997</year>
<article-title>Identification of three novel mutations in hereditary protein S deficiency</article-title>. <source>Thromb. Haemost.</source>
<volume>77</volume>:<fpage>21</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">9031443</pub-id></mixed-citation></ref><ref id="ccr31226-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ccr31226-cit-0005">
<string-name>
<surname>Pintao</surname>, <given-names>M. C.</given-names>
</string-name>, <string-name>
<given-names>D. D.</given-names>
<surname>Ribeiro</surname>
</string-name>, <string-name>
<given-names>I. D.</given-names>
<surname>Bezemer</surname>
</string-name>, <string-name>
<given-names>A. A.</given-names>
<surname>Garcia</surname>
</string-name>, <string-name>
<given-names>M. C.</given-names>
<surname>de Visser</surname>
</string-name>, <string-name>
<given-names>C. J.</given-names>
<surname>Doggen</surname>
</string-name>, et al. <year>2013</year>
<article-title>Protein S levels and the risk of venous thrombosis: results from the MEGA case&#x02010;control study</article-title>. <source>Blood</source>
<volume>122</volume>:<fpage>3210</fpage>&#x02013;<lpage>3219</lpage>.<pub-id pub-id-type="pmid">24014240</pub-id></mixed-citation></ref></ref-list></back></article>